| Myasthenia Gravis, Generalized
Rystiggo vs Vyvgart
Side-by-side clinical, coverage, and cost comparison for myasthenia gravis, generalized.Deep comparison between: Rystiggo vs Vyvgart with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVyvgart has a higher rate of injection site reactions vs Rystiggo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vyvgart but not Rystiggo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Rystiggo
Vyvgart
At A Glance
SC injection
Once weekly (6-week cycles)
FcRn blocker
IV infusion
Once weekly for 4 weeks per cycle
FcRn antagonist
Indications
- Myasthenia Gravis, Generalized
- Myasthenia Gravis, Generalized
Dosing
Myasthenia Gravis, Generalized Weight-based SC infusion once weekly for 6 weeks: less than 50 kg: 420 mg (3 mL); 50 to less than 100 kg: 560 mg (4 mL); 100 kg and above: 840 mg (6 mL); administer at up to 20 mL/hour; subsequent cycles based on clinical evaluation, no sooner than 63 days from start of previous cycle.
Myasthenia Gravis, Generalized 10 mg/kg (1200 mg if >=120 kg) as IV infusion over 1 hour once weekly for 4 weeks; subsequent cycles based on clinical evaluation.
Contraindications
—
- Serious hypersensitivity to efgartigimod alfa products or any excipient of VYVGART
Adverse Reactions
Most common (>=10%) headache, infections, diarrhea, pyrexia, hypersensitivity reactions, nausea
Serious infections (including fatal pneumonia), aseptic meningitis
Postmarketing herpes zoster
Most common (>=5%) Respiratory tract infection, headache, urinary tract infection, paraesthesia, myalgia
Postmarketing Hypersensitivity reactions including anaphylaxis and hypotension, infusion-related reactions
Pharmacology
FcRn antagonist; rozanolixizumab-noli is a humanized IgG4 monoclonal antibody that binds to the neonatal Fc receptor (FcRn), reducing circulating IgG levels and pathogenic AChR and MuSK autoantibody concentrations in patients with generalized myasthenia gravis.
Efgartigimod alfa-fcab is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), reducing circulating IgG levels and AChR autoantibody levels in patients with generalized myasthenia gravis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Rystiggo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Vyvgart
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Rystiggo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Vyvgart
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Rystiggo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Vyvgart
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Myasthenia Gravis - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Myasthenia Gravis - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RystiggoView full Rystiggo profile
VyvgartView full Vyvgart profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.